for example f Exelon when compared to placebo. Figure 7: Time Course of the Change from Baseline in ADAS-cog Score for Patients Completing 24 Weeks of Treatment in Study 4 Figure 8 is a histogram of the distribution of patients scores on the ADCS-CGIC (Alzheimer s Disease Cooperative Study - Clinician s Global Impression of Change) at 24 weeks. The mean difference in change scores between the Exelon and placebo groups from baseline was 0.5 points. This difference was statistically significant in favor of Exelon treatment. Figure 8: Distribution of ADCS-CGIC Scores for Patients Completing 24 Weeks of Treatment in Study 4 Patients age demanding
Photo :f Exelon when compared to placebo. Figure 7: Time Course of the Change from Baseline in ADAS-cog Score for Patients Completing 24 Weeks of Treatment in Study 4 Figure 8 is a histogram of the distribution of patients scores on the ADCS-CGIC (Alzheimer s Disease Cooperative Study - Clinician s Global Impression of Change) at 24 weeks. The mean difference in change scores between the Exelon and placebo groups from baseline was 0.5 points. This difference was statistically significant in favor of Exelon treatment. Figure 8: Distribution of ADCS-CGIC Scores for Patients Completing 24 Weeks of Treatment in Study 4 Patients age for you to gender i assumed
worried f Exelon when compared to placebo. Figure 7: Time Course of the Change from Baseline in ADAS-cog Score for Patients Completing 24 Weeks of Treatment in Study 4 Figure 8 is a histogram of the distribution of patients scores on the ADCS-CGIC (Alzheimer s Disease Cooperative Study - Clinician s Global Impression of Change) at 24 weeks. The mean difference in change scores between the Exelon and placebo groups from baseline was 0.5 points. This difference was statistically significant in favor of Exelon treatment. Figure 8: Distribution of ADCS-CGIC Scores for Patients Completing 24 Weeks of Treatment in Study 4 Patients age abroad
EmoticonEmoticon